Core Viewpoint - Huashan Biological Vaccine Co., Ltd. is preparing for the public offering of its A-shares on the ChiNext board, with specific commitments made by its controlling shareholders regarding share lock-up and trading practices [1][11][19]. Summary by Sections Initial Public Offering Overview - The company plans to issue 40,010,000 shares, increasing its total share capital from 360,000,000 to 400,010,000 shares as of February 18, 2022 [1]. - Following a stock split of 10 shares for every 5 shares, the total share capital will rise to 600,015,000 shares [2]. Share Lock-up and Release - As of the date of the verification opinion, the total share capital stands at 601,027,500 shares, with 141,648,150 shares (23.57%) being unrestricted and 459,000,000 shares (76.37%) subject to lock-up [2][20]. - The lock-up period for the shares is extended by 6 months due to specific conditions being triggered, with the release date set for August 18, 2025 [2][3]. Commitments by Shareholders - The controlling shareholders, Huashan Biological and Hong Kong Kexin, have made commitments regarding the non-transfer of shares during the initial 36 months post-listing and conditions under which the lock-up period may be extended [3][4]. - Shareholders are obligated to comply with regulations regarding share reduction and must avoid any actions that could harm the interests of other shareholders [15][16]. Corporate Governance and Compliance - The company has established measures to ensure compliance with laws and regulations, including maintaining the independence of its operations and avoiding conflicts of interest with its controlling shareholders [14][19]. - The commitments made by the controlling shareholders are legally binding and will remain effective as long as they hold shares in the company [18][19]. Financial and Operational Commitments - The company has outlined a profit distribution policy and commitments to ensure that shareholder returns are met following the public offering [19][20]. - Measures are in place to stabilize the stock price and protect the interests of minority investors, including potential buyback plans if stock prices fall below certain thresholds [11][12].
华兰疫苗: 华泰联合证券有限责任公司关于华兰生物疫苗股份有限公司部分首次公开发行前已发行股份上市流通的核查意见